- Zoster vaccine live (ZVL) reduces herpes zoster (HZ)-associated postherpetic neuralgia (PHN) pain duration and severity in both sexes, even when HZ occurs despite vaccination.
Why this matters
- Include education about severe PHN pain prevention when encouraging uptake of HZ vaccine.
- Ensure patients know that even if ZVL does not offer 100% protection against developing HZ, it might improve overall outcomes.
- 1018 PCR-confirmed patients with HZ (509, 509; ZVL vaccinated, unvaccinated, respectively).
- 68.6% patients ≥70 years at diagnosis, 62.8% (639) women.
- At baseline, risk for worst pain ≥3 (75.4% vs 78.7%), ≥7 pain points (40.9% vs 46.5%), vaccinated vs unvaccinated, respectively.
- From 30 to 60 to 90 days, percentage reporting pain continued to decline:
- Day 90: risk for worst pain ≥3 reported by 9.2% vs 15.4%, vaccinated vs unvaccinated, respectively (adjusted relative risk [aRR], 0.594; 95% CI, 0.413-0.854).
- Risk for worst pain ≥7 reported by 2.0% vs 4.8%, vaccinated vs unvaccinated, respectively (aRR, 0.332; 95% CI, 0.153-0.721).
- PHN risk increased with age (4.6% vs 11.1%, vaccinated vs unvaccinated, respectively).
- Prospective cohort analysis of ZVL vaccinated, unvaccinated patients with laboratory-confirmed HZ to assess HZ-related pain progression, ZVL effect on PHN.
- Funding: NIH.
- Participation bias.
- Minimal nonresponse bias.
- Low subgroup sample sizes.